Acknowledgments This research was financially supported by the Major Projects for Drug Innovation and Development from the National Science and Technology of China (2012ZX09304004). Conflict of Interests The authors declare that there is no conflict of interests regarding the publication of this paper.
Systemic chemotherapy in cancer patients with liver tumors or liver metastases shows up to now especially with respect to the prolongation of overall survival insufficient results probably due to not high enough local tumor drug dosages [1].

Collins and coworkers could show that the response rates can be doubled when the drug concentration is increased by a factor of 10 [2]. However, systemic applied cytostatic Inhibitors,research,lifescience,medical drugs may worsen the quality of life of patients by sometimes very severe adverse side effects especially when used in high dosages. Those cytotoxic side effects limit the use of efficient dosages. Thus, since several years various techniques Inhibitors,research,lifescience,medical were investigated and used for intra-arterial administration of certain

cytostatic drugs, which allows higher drug concentrations [3]. It could be shown, for example, that regional infusion of 5-fluorouracil (5-FU) increases liver exposure to the drug by a factor Inhibitors,research,lifescience,medical of 100 when compared to SNS032 intravenous application route [4]. In fact, meanwhile, several randomized clinical trials in colon cancer patients suffering from liver metastases have shown that the intra-arterial application of 5-FU or floxuridine leads to increased response rates with a tendency to prolongation of the overall survival [5–10]. However, the liver is a high blood flow organ receiving

Inhibitors,research,lifescience,medical a large fraction of the cardiac output leading immediately to transportation of the drug outside the target organ [11]. In this context, reduction of the regional blood flow by occluding the vascular bed when administering the drug is one of the most important factors for an effective drug delivery into the liver tumor via intra-arterial application [12]. Several embolization materials were tested and used to reduce the regional Inhibitors,research,lifescience,medical blood flow [3, 4-Aminobutyrate aminotransferase 11, 12]. However, some of these materials lead to permanent vascular occlusion and thus limit repeated treatments [3, 11, 12]. Meanwhile, the implantation of degradable starch microspheres (DSM) to TACE is accepted by several publications showing the near-term reproducibility, higher accumulation rates of the coapplied drugs, less toxicity though significantly reduced cytotoxic peak plasma concentrations, less postembolization syndrome, and the unique possibilities of combination with drugs and other treatment techniques [3, 11, 13–19]. DSM are produced from partly hydrolysed starch, cross-linked, and substituted with glycerol ether groups and are degradable by α-amylase [20]. The complete degradation of DSM by α-amylase causes only a short-lasting temporary vascular occlusion, which allows a repeated application of DSM in TACE [3].